EBS · Insider Trading
Emergent Biosolutions, Inc.
Every open-market purchase and sale reported by EBS officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-10-07 | Donald W DeGolyer | Director | Sell | −17,800 | −$126.20K |
| 2026-10-05 | Paul Anthony Williams | SVP, Products Business | Sell | −3,000 | −$19.59K |
| 2026-07-02 | Paul Anthony Williams | SVP, Products Business | Sell | −3,000 | −$25.20K |
| 2026-06-10 | William Hartzel | SVP, Bioservices | F | −1,741 | −$13.93K |
| 2026-06-10 | Coleen Glessner | EVP, Quality & Ethics, and CPL | F | −2,018 | −$16.14K |
| 2026-06-10 | Richard S Lindahl | EVP, Chief Financial Officer | F | −3,964 | −$31.71K |
| 2026-06-10 | Paul Anthony Williams | SVP, Products Business | F | −694 | −$5.55K |
| 2026-05-04 | Ronald Richard | Director | A | +25,344 | — |
| 2026-05-04 | Neal Franklin Fowler | Director | A | +25,344 | — |
| 2026-05-04 | Marvin L White | Director | A | +25,344 | — |
| 2026-05-04 | Donald W DeGolyer | Director | MIXED | +9,863 | −$129.99K |
| 2026-05-04 | John D Fowler Jr | Director | A | +25,344 | — |
| 2026-05-04 | Sujata Tyagi Dayal | Director | MIXED | +11,583 | −$115.61K |
| 2026-05-04 | Zsolt Harsanyi | Chairman | A | +25,344 | — |
| 2026-05-04 | Keith Katkin | Director | MIXED | +9,863 | −$128.18K |
| 2026-05-04 | Kathryn C Zoon | Director | MIXED | +8,142 | −$144.45K |
| 2026-05-01 | Richard S Lindahl | EVP, Chief Financial Officer | A | +162,680 | — |
| 2026-05-01 | Simon C Lowry | SVP, R&D, CMO | A | +100,111 | — |
| 2026-05-01 | Joseph C Papa | President and CEO | A | +187,708 | — |
| 2026-05-01 | Jessica Perl | SVP, General Counsel, Corp Sec | A | +104,282 | — |
| 2026-05-01 | Coleen Glessner | EVP, Quality & Ethics, and CPL | A | +100,111 | — |
| 2026-05-01 | William Hartzel | SVP, Bioservices | A | +100,111 | — |
| 2026-05-01 | Paul Anthony Williams | SVP, Products Business | A | +100,111 | — |
| 2026-04-03 | Paul Anthony Williams | SVP, Products Business | Sell | −4,000 | −$33.76K |
| 2026-03-06 | Richard S Lindahl | EVP, Chief Financial Officer | H | −40,284 deriv. | — |
| 2026-03-05 | Paul Anthony Williams | SVP, Products Business | F | −9,397 | −$79.31K |
| 2026-03-05 | Jessica Perl | SVP, General Counsel, Corp Sec | F | −6,465 | −$54.56K |
| 2026-03-05 | William Hartzel | SVP, Bioservices | F | −9,493 | −$80.12K |
| 2026-03-05 | Richard S Lindahl | EVP, Chief Financial Officer | F | −23,650 | −$199.61K |
| 2026-03-05 | John D Fowler Jr | Director | A | +5,006 | +$45.00K |
| 2026-03-05 | Joseph C Papa | President and CEO | F | −37,055 | −$312.74K |
| 2026-03-05 | Coleen Glessner | EVP, Quality & Ethics, and CPL | F | −8,199 | −$69.20K |
| 2026-03-05 | Simon C Lowry | SVP, R&D, CMO | F | −10,636 | −$89.77K |
| 2026-03-03 | Richard S Lindahl | EVP, Chief Financial Officer | F | −683 | −$5.57K |
| 2026-03-03 | Paul Anthony Williams | SVP, Products Business | F | −116 | −$945 |
| 2026-03-03 | Coleen Glessner | EVP, Quality & Ethics, and CPL | F | −313 | −$2.55K |
| 2026-02-10 | Paul Anthony Williams | SVP, Products Business | MIXED | −9,677 | −$105.67K |
| 2026-02-10 | Coleen Glessner | EVP, Quality & Ethics, and CPL | MIXED | −31,699 | −$346.15K |
| 2026-02-10 | Richard S Lindahl | EVP, Chief Financial Officer | MIXED | −51,797 | −$565.62K |
| 2026-02-10 | William Hartzel | SVP, Bioservices | MIXED | −6,401 | −$69.90K |
| 2026-02-10 | Jessica Perl | SVP, General Counsel, Corp Sec | F | −918 | −$10.13K |
| 2025-12-16 | Simon C Lowry | SVP, R&D, CMO | F | −3,543 | −$40.43K |
| 2025-12-09 | Ronald Richard | Director | MIXED | −7,100 | −$263.08K |
| 2025-11-13 | William Hartzel | SVP, Bioservices | F | −610 | −$6.64K |
| 2025-11-12 | Donald W DeGolyer | Director | Sell | −17,801 | −$187.62K |
| 2025-11-10 | Sujata Tyagi Dayal | Director | Sell | −8,552 | −$85.52K |
| 2025-10-17 | Richard S Lindahl | EVP, Chief Financial Officer | F | −4,995 | −$47.95K |
| 2025-10-16 | Coleen Glessner | EVP, Quality & Ethics, and CPL | Sell | −30,608 | −$306.08K |
| 2025-08-18 | Kathryn C Zoon | Director | Sell | −7,086 | −$62.85K |
| 2025-08-13 | Donald W DeGolyer | Director | Sell | −7,844 | −$67.83K |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| Joseph C Papa | President and CEO | 493,153 | $3.13M |
| Richard S Lindahl | EVP, Chief Financial Officer | 374,083 | $2.37M |
| Coleen Glessner | EVP, Quality & Ethics, and CPL | 202,201 | $1.28M |
| William Hartzel | SVP, Bioservices | 185,558 | $1.18M |
| Simon C Lowry | SVP, R&D, CMO | 177,914 | $1.13M |
| Jessica Perl | SVP, General Counsel, Corp Sec | 165,286 | $1.05M |
| Neal Franklin Fowler | Director | 160,847 | $1.02M |
| Paul Anthony Williams | SVP, Products Business | 156,098 | $989.66K |
| Zsolt Harsanyi | Chairman | 149,076 | $945.14K |
| Louis W Sullivan | Director | 139,098 | $881.88K |
| Ronald Richard | Director | 123,761 | $784.64K |
| Sujata Tyagi Dayal | Director | 114,324 | $724.81K |
| Marvin L White | Director | 113,839 | $721.74K |
| Donald W DeGolyer | Director | 111,921 | $709.58K |
| Keith Katkin | Director | 111,775 | $708.65K |
| Kathryn C Zoon | Director | 79,941 | $506.83K |
| John D Fowler Jr | Director | 30,350 | $192.42K |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the EBS quote page; the site-wide leaderboard is on the insider transactions hub.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.